Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-20
    E.g., 2018-10-20

Archive Search

8 results
12:00 AM, Jul 30, 2012  |  BC Week In Review | Clinical News  |  Regulatory

Clopidogrel Genetic Absorption Activation Panel regulatory update

response to cardiovascular drug Plavix clopidogrel. The test detects deficiencies associated with genes CYP2C19 and ABCB1
12:00 AM, May 22, 2006  |  BC Week In Review | Clinical News  |  Regulatory

Tesmilifene regulatory update

Tesmilifene is a small molecule chemopotentiator that kills multi-drug resistant cells through its interaction with P glycoprotein
12:00 AM, Jun 30, 2003  |  BC Week In Review | Clinical News  |  Regulatory

Small molecule chemopotentiator that kills multi-drug resistant cells through its interaction with P glycoprotein regulatory update

Ontario   Product: Small molecule chemopotentiator that kills multi-drug resistant cells through its interaction with P glycoprotein
12:00 AM, Oct 07, 2002  |  BC Week In Review | Clinical News  |  Regulatory

Tariquidar regulatory update

see BioCentury, Aug. 20, 2001). QLT Inc. (QLTI; TSE:QLT), Vancouver, B.C.   Product: Tariquidar (XR9576) P-glycoprotein
12:00 AM, Apr 24, 2000  |  BC Week In Review | Clinical News  |  Regulatory

Oral bioavailability technology regulatory update

and 6,028,054 covering the use of inhibitors of cytochrome P450 3A ( CYP3A ) or P-glycoprotein
Pgp), respectively, to increase the bioavailability of orally administered compounds by improving uptake into the blood …
12:00 AM, Nov 17, 1997  |  BC Week In Review | Clinical News  |  Regulatory

Immunomedics regulatory update

received U.S. Patent No. 5,686,578 covering a bi-specific antibody that binds the multidrug resistance pump P-glycoprotein
known as MDR1 ), as well as cancer cells or infectious agents, to diagnose or treat …
12:00 AM, Sep 30, 1996  |  BC Week In Review | Clinical News  |  Regulatory

Vertex regulatory update

resistance, which limits the efficacy of many chemotherapy regimens. In laboratory studies, VX-853 blocks both P-glycoprotein
12:00 AM, Jul 25, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Ingenex regulatory update

decreased accumulation of chemotherapeutic agents within tumor cells, due to a pumping mechanism associated with P-glycoprotein
a cell-surface protein. Ingenex is developing the IGX MAb to inhibit the activity of P-glycoprotein as …